STELAZINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STELAZINE is an injectable small-molecule antipsychotic approved in 1959 for psychiatric indications. The specific mechanism of action and therapeutic indications are not detailed in available data, but the injectable formulation suggests use in acute psychiatric settings or patient populations requiring parenteral administration.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential downsizing or reallocation of brand resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STELAZINE currently has zero linked job openings, reflecting its mature, declining lifecycle stage. Career opportunities are primarily in managed care and transition roles rather than growth-oriented positions.
Brand ManagerField Sales
Worked on STELAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.